	US 11,884,723 B2
	Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
Nicolas Poirier, Treillieres (FR); Vanessa Gauttier, Reze (FR); Caroline Mary, Sainte-Pazanne (FR); Sabrina Pengam, Sainte-Luce-sur-Loire (FR); and Bernard Vanhove, Reze (FR)
Assigned to OSE IMMUNOTHERAPEUTICS, Nantes (FR)
Appl. No. 16/979,627
Filed by OSE IMMUNOTHERAPEUTICS, Nantes (FR)
PCT Filed Mar. 13, 2019, PCT No. PCT/EP2019/056250 § 371(c)(1), (2) Date Sep. 10, 2020, PCT Pub. No. WO2019/175218, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. 18305271 (EP), filed on Mar. 13, 2018.
Prior Publication US 2021/0040206 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

20 Claims

1. A method of treating a cancer in a subject that expresses SIRPa v1, the method comprising administering to a subject a therapeutic amount of an anti-human SIRPa antibody, antigen-binding fragment thereof, or modified antibody thereof, which comprises:

a) a heavy chain variable domain comprising HCDR1, HCDR2 and HCDR3, wherein: HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; and

b) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 17, wherein the antibody, antigen-binding fragment thereof, or modified antibody thereof, enhances cross presentation of an antigen expressed in said disease and is involved in eliciting a T cell response suitable for the treatment of said disease.